Atrial fibrillation and flutterMANAGEMENT

CARDIOVASCULAR PRESENTATIONS · 12 SECTIONS

⚲

566 items

☷ Legend

01Approach to the Critical Patient/attcp66

Initial stabilization

›Initial priorities

›Airway protection triggers

›Depressed consciousness with hypoventilation

›Refractory hypoxemia

›Breathing support

›Oxygen for SpO2 below local target

›Noninvasive ventilation for acute pulmonary edema

›Circulation actions

›If hypotension with altered mentation, immediate synchronized cardioversion

›If shock or ischemic chest pain, immediate synchronized cardioversion

›If acute pulmonary edema, immediate synchronized cardioversion

›Monitoring

›Continuous ECG

›NIBP every 3 to 5 minutes or arterial line if unstable

›Pulse oximetry

›Rhythm identification

›Atrial fibrillation features

›Irregularly irregular R R intervals

›No discrete P waves

›Atrial flutter features

›Regular narrow complex tachycardia with ventricular rate often near 150

›Sawtooth flutter waves in inferior leads

›Wide complex tachycardia safety assumptions

›If wide and irregular, treat as atrial fibrillation with pre-excitation until proven otherwise

›If wide and regular, consider ventricular tachycardia until proven otherwise

›Hemodynamic instability definition

›Instability criteria

›Systolic BP below 90 mmHg with hypoperfusion

›Ongoing ischemic chest pain

›Acute heart failure with pulmonary edema

›Altered mental status attributed to arrhythmia

›Immediate consult triggers

›Cardiology or electrophysiology

›Suspected pre-excitation

›Refractory rapid ventricular response

›Need for urgent rhythm control with complex comorbidity

›Critical care

›Persistent instability after initial intervention

›Need for vasoactive infusion

Key decision points

›Management pathway selection

›Unstable atrial fibrillation or flutter

›Synchronized cardioversion pathway

›Peri-procedural anticoagulation consideration

›Stable with rapid ventricular response

›Rate control pathway

›Rhythm control option selection based on onset and stroke risk

›Stable without rapid ventricular response

›Anticoagulation and outpatient rhythm strategy

›Onset timing framework

›Onset under 48 hours

›Rhythm control option with peri-procedural anticoagulation based on stroke risk

›Onset over 48 hours or unknown

›Anticoagulation 3 weeks before elective cardioversion

›TEE guided cardioversion with immediate anticoagulation alternative

›Anticoagulation minimum 4 weeks after cardioversion

›Reversible trigger screen

›Trigger categories

›Sepsis or systemic infection

›Hypovolemia or hemorrhage

›Hypoxia or COPD exacerbation

›Pulmonary embolism

›Thyrotoxicosis

›Alcohol or stimulant exposure

›Postoperative state

›Acute coronary syndrome

›Decompensated heart failure

02History/hx63

Presenting features and timing

›Symptom characterization

›Palpitations

›Abrupt onset versus gradual onset

›Intermittent versus persistent

›Dyspnea

›Orthopnea

›Reduced exercise tolerance

›Chest discomfort

›Exertional pattern

›Rest pain pattern

›Presyncope or syncope

›Exertional syncope concern

›Injury during event

›Neurologic symptoms

›Focal weakness

›Aphasia

›Timing and duration

›Symptom onset clock time

›Under 48 hours

›Over 48 hours

›Unknown onset

›Prior episodes

›Paroxysmal pattern

›Persistent pattern

›Longstanding persistent pattern

Risk factors and comorbidities

›Stroke risk factors

›Congestive heart failure history

›Hypertension history

›Diabetes mellitus history

›Prior stroke or TIA

›Vascular disease history

›Age 65 to 74 years

›Age 75 years or older

›Female sex

›Bleeding risk context

›Prior major bleeding

›Prior intracranial hemorrhage

›Active GI bleed symptoms

›Chronic liver disease

›Chronic kidney disease

›Concomitant antiplatelet use

›Structural heart disease

›Valvular disease

›Cardiomyopathy

›Congenital heart disease

›Prior cardiac surgery

›Potential triggers

›Fever

›Cough or sputum change

›Recent surgery

›Alcohol binge

›Stimulant use

›Thyroid symptoms

Medications and anticoagulation status

›Current cardiac medications

›Beta blocker use

›Non-dihydropyridine calcium channel blocker use

›Digoxin use

›Antiarrhythmic use

›Anticoagulation details

›DOAC name and last dose time

›Warfarin use and last INR value

›Missed doses in past 3 weeks

›Antiplatelet use

03Physical Exam/exam44

Focused cardiovascular and volume assessment

›Hemodynamics

›Blood pressure trend

›Hypotension with signs of shock

›Hypertension suggesting catecholamine surge

›Heart rate

›Resting ventricular rate above 110

›Ventricular rate near 150 suggesting flutter with 2 to 1 conduction

›Peripheral perfusion

›Cool extremities

›Delayed capillary refill

›Cardiac exam

›Rhythm regularity

›Irregularly irregular pulse

›Regular tachycardia with fixed rate

›Murmur assessment

›Mitral stenosis suspicion

›New murmur with heart failure

›Volume status

›JVP elevation

›Right heart strain concern

›Fluid overload concern

›Peripheral edema

›New bilateral edema

›Unilateral edema with DVT concern

Pulmonary and neurologic screening

›Respiratory status

›Work of breathing

›Accessory muscle use

›Speaking in short phrases

›Lung auscultation

›Crackles suggesting pulmonary edema

›Wheeze suggesting bronchospasm

›Neurologic status

›Mental status

›Acute delirium or confusion

›Reduced level of consciousness

›Focal deficits

›Facial droop

›Arm drift

›Speech abnormality

PITFALLS

›Common misses

›Mislabeling atrial flutter as atrial fibrillation on monitor strip

›Treating irregular wide complex tachycardia with AV nodal blockers in pre-excitation

›Overlooking sepsis or pulmonary embolism as the driver of tachyarrhythmia

›Assuming symptom onset time is reliable without corroboration

04Differential Diagnosis/ddx42

Life-threatening and mimics

›Dangerous diagnoses

›Acute coronary syndrome

›ICD-10 I21

›SNOMED CT acute myocardial infarction

›Pulmonary embolism

›ICD-10 I26

›SNOMED CT pulmonary embolism

›Sepsis

›ICD-10 A41.9

›SNOMED CT sepsis

›Thyroid storm

›ICD-10 E05.91

›SNOMED CT thyroid storm

›Ventricular tachycardia

›ICD-10 I47.2

›SNOMED CT ventricular tachycardia

›Arrhythmia differential

›Atrial fibrillation

›ICD-10 I48.0 to I48.2

›SNOMED CT atrial fibrillation

›Typical atrial flutter

›ICD-10 I48.3

›SNOMED CT atrial flutter

›SVT AVNRT or AVRT

›ICD-10 I47.1

›SNOMED CT supraventricular tachycardia

›Multifocal atrial tachycardia

›ICD-10 I47.1

›SNOMED CT multifocal atrial tachycardia

›Atrial tachycardia

›ICD-10 I47.1

›SNOMED CT atrial tachycardia

›Non-arrhythmic causes of tachycardia

›Hemorrhage

›ICD-10 R58

›SNOMED CT hemorrhage

›Hypovolemia

›ICD-10 E86.1

›SNOMED CT hypovolemia

›Hypoxia

›ICD-10 R09.02

›SNOMED CT hypoxemia

05Laboratory Tests/lt37

Core ED labs

›Baseline laboratory panel

›Electrolytes and renal function

›Sodium mmol/L

›Potassium mmol/L

›Magnesium mmol/L

›Creatinine and eGFR

›CBC

›Anemia as contributor to demand ischemia

›Leukocytosis as infection clue

›Glucose mmol/L

›Hypoglycemia as altered mentation mimic

›Severe hyperglycemia as stress marker

Cause and complication directed labs

›Trigger evaluation

›Thyroid testing

›TSH for new atrial fibrillation without clear trigger

›Free T4 if TSH suppressed

›Infection evaluation

›Lactate mmol/L for suspected sepsis

›Blood cultures if febrile with sepsis concern

›Cardiac injury evaluation

›High sensitivity troponin

›Dynamic change supporting ACS

›Mild elevation possible in tachycardia and heart failure

›BNP or NT-proBNP

›Heart failure support in dyspnea

›Limited specificity in renal dysfunction

Anticoagulation and procedural labs

›Anticoagulation readiness

›INR for warfarin users

›Therapeutic range 2.0 to 3.0 for nonvalvular atrial fibrillation

›Higher target range for mechanical valves per valve type

›aPTT for unfractionated heparin titration

›Baseline before infusion

›Repeat per protocol

›Procedure safety

›Pregnancy test for patients with pregnancy potential

›Medication and imaging implications

›Cardioversion generally safe in pregnancy

06Diagnostic Tests/dt46

Scoring Systems

›Risk stratification tools

›CHA2DS2-VASc stroke risk

›Congestive heart failure 1 point

›Hypertension 1 point

›Age 75 years or older 2 points

›Diabetes mellitus 1 point

›Prior stroke or TIA 2 points

›Vascular disease 1 point

›Age 65 to 74 years 1 point

›Female sex 1 point

›HAS-BLED bleeding risk context

›Hypertension uncontrolled 1 point

›Abnormal renal function 1 point

›Abnormal liver function 1 point

›Stroke history 1 point

›Bleeding history 1 point

›Labile INR 1 point

›Elderly age over 65 years 1 point

›Drugs predisposing to bleeding 1 point

›Alcohol excess 1 point

MRI

›MRI roles

›Brain MRI

›Acute stroke evaluation when CT nondiagnostic and symptoms persistent

›Not a prerequisite for anticoagulation decisions in stable patients

›Cardiac MRI

›Selected cardiomyopathy evaluation in recurrent atrial fibrillation

›Not an ED routine test

›CT roles

›CT pulmonary angiography

›PE evaluation when clinical suspicion high

›Tachyarrhythmia as possible PE manifestation

›CT head noncontrast

›New focal neurologic deficit

›Head trauma with anticoagulation

›CT coronary angiography

›Selected chest pain evaluation per local pathways

Ultrasound

›Point of care ultrasound

›Cardiac POCUS

›LV function gross assessment

›Pericardial effusion assessment

›RV dilation suggesting PE in appropriate context

›Lung ultrasound

›B lines supporting pulmonary edema

›Pleural effusion assessment

›Lower extremity venous ultrasound

›Proximal DVT assessment when PE suspected

07Disposition/dispo30

Level of care and admission criteria

›Admission indications

›Persistent hemodynamic instability

›Recurrent hypotension

›Need for vasoactive support

›Acute heart failure

›Ongoing oxygen requirement

›Need for IV diuresis and monitoring

›Suspected ACS

›Dynamic troponin rise

›Ongoing ischemic symptoms

›Stroke or TIA concern

›Persistent neurologic deficit

›Need for stroke pathway and imaging

›Pre-excitation with atrial fibrillation

›Need for monitored antiarrhythmic therapy

›Electrophysiology evaluation

›ICU or stepdown indications

›Post cardioversion with ongoing instability

›Refractory rate requiring continuous infusion

›Significant comorbid decompensation

ED discharge pathway

›Discharge candidates

›Hemodynamic stability throughout ED stay

›Ventricular rate controlled at rest

›No active ischemia evidence

›No acute heart failure requiring IV therapy

›Clear anticoagulation plan with follow-up

›Follow-up targets

›Primary care or cardiology follow-up within 7 days

›Anticoagulation follow-up within 3 to 5 days if warfarin initiation

›Electrophysiology referral for typical flutter ablation candidacy

08Treatment/t132

Unstable atrial fibrillation or flutter

›Synchronized cardioversion

›Energy selection

›Biphasic 120 to 200 J initial for atrial fibrillation

›Biphasic 50 to 100 J initial for typical atrial flutter

›Sedation considerations

›Etomidate IV 0.1 to 0.2 mg/kg for brief deep sedation

›Propofol IV 0.5 to 1 mg/kg with caution in hypotension

›Ketamine IV 1 mg/kg for bronchospasm or hypotension risk

›Anticoagulation around emergent cardioversion

›If onset over 48 hours or unknown, anticoagulation as soon as feasible unless contraindicated

›If onset under 48 hours, anticoagulation decision based on stroke risk and clinical context

Stable rate control

›Rate control targets

›Resting ventricular rate under 110 for stable patients

›Resting ventricular rate under 100 for persistent symptoms or LV dysfunction

›Beta blocker options

›Metoprolol IV

›Metoprolol IV 2.5 to 5 mg

›Repeat every 5 minutes

›Total maximum 15 mg

›Avoid in acute decompensated heart failure with hypoperfusion

›Avoid in severe asthma with active bronchospasm

›Esmolol IV infusion

›Esmolol IV bolus 500 mcg/kg over 1 minute

›Infusion 50 mcg/kg/min

›Titrate every 5 minutes by 50 mcg/kg/min

›Maximum 200 mcg/kg/min

›Useful when rapid offset desired

›Non-dihydropyridine calcium channel blockers

›Diltiazem IV bolus then infusion

›Diltiazem IV 0.25 mg/kg over 2 minutes

›Second bolus 0.35 mg/kg after 15 minutes if inadequate

›Infusion 5 to 15 mg/hour

›Titrate by 2.5 mg/hour every 15 minutes

›Avoid in HFrEF with significant LV systolic dysfunction

›Verapamil IV

›Verapamil IV 2.5 to 5 mg over 2 minutes

›Repeat 5 to 10 mg after 15 to 30 minutes if needed

›Maximum 20 mg

›Avoid in hypotension

›Digoxin

›Digoxin IV loading

›Digoxin IV 0.25 mg

›Repeat 0.25 mg every 6 hours

›Total 1 mg over 24 hours

›Slower onset

›Useful in sedentary patients with hypotension limiting other agents

›Combination therapy cautions

›Beta blocker plus calcium channel blocker risk

›Hypotension

›AV block

Stable rhythm control

›Rhythm control selection

›Pharmacologic cardioversion options

›Ibutilide IV for flutter and atrial fibrillation

›Ibutilide IV 1 mg over 10 minutes if weight 60 kg or more

›Second dose 1 mg over 10 minutes after 10 minutes if needed

›Continuous telemetry minimum 4 hours

›Torsades risk increased with low potassium or low magnesium

›Procainamide IV for atrial fibrillation with pre-excitation

›Procainamide IV 15 to 17 mg/kg over 30 to 60 minutes

›Stop if QRS widens over 50 percent

›Stop if hypotension develops

›Avoid in severe heart failure

›Amiodarone IV for atrial fibrillation with structural heart disease

›Amiodarone IV 150 mg over 10 minutes

›Infusion 1 mg/min for 6 hours

›Infusion 0.5 mg/min for 18 hours

›Slower cardioversion than class IC agents

›Electrical cardioversion in stable patient

›Suitable when symptom burden high and onset under 48 hours

›Suitable when TEE excludes atrial thrombus

›Pre-excitation and irregular wide complex tachycardia

›Avoid AV nodal blockers

›Adenosine

›Diltiazem

›Verapamil

›Beta blockers

›Digoxin

›Preferred agents

›Procainamide IV protocol

›See procainamide dosing section

›Continuous ECG for QRS widening

›If unstable, synchronized cardioversion

›Immediate pathway

Anticoagulation and stroke prevention

›Anticoagulation indication framework

›Nonvalvular atrial fibrillation or flutter

›CHA2DS2-VASc 0 in men

›No anticoagulation usually

›CHA2DS2-VASc 1 in men

›Anticoagulation consideration based on shared decision making

›CHA2DS2-VASc 1 in women from sex alone

›No anticoagulation usually

›CHA2DS2-VASc 2 or more in men

›Long term anticoagulation recommended

›CHA2DS2-VASc 3 or more in women

›Long term anticoagulation recommended

›Valvular atrial fibrillation

›Moderate to severe rheumatic mitral stenosis

›Warfarin preferred

›Mechanical heart valve

›Warfarin required

›DOAC options for nonvalvular atrial fibrillation

›Apixaban

›Apixaban 5 mg PO twice daily

›Reduce to 2.5 mg PO twice daily when dose reduction criteria met

›Rivaroxaban

›Rivaroxaban 20 mg PO daily with food

›Dose reduction for renal impairment per product monograph

›Dabigatran

›Dabigatran 150 mg PO twice daily

›Dose reduction for renal impairment per product monograph

›Edoxaban

›Edoxaban 60 mg PO daily

›Dose reduction for renal impairment per product monograph

›Warfarin

›Warfarin initiation

›INR target 2.0 to 3.0 for nonvalvular atrial fibrillation

›Bridging not routinely required for nonvalvular atrial fibrillation

›Peri-cardioversion anticoagulation

›Onset over 48 hours or unknown

›Anticoagulation minimum 3 weeks before elective cardioversion

›Anticoagulation minimum 4 weeks after cardioversion

›TEE guided strategy

›Immediate anticoagulation then TEE to exclude thrombus

›Cardioversion after negative TEE

›Anticoagulation minimum 4 weeks after cardioversion

Evidence and guideline signals

›Guideline classes

›Hemodynamic instability with atrial fibrillation or flutter

›Synchronized cardioversion Class I recommendation

›Anticoagulation for elevated CHA2DS2-VASc

›Long term oral anticoagulation Class I recommendation

›AV nodal blocking agents for acute rate control in stable patients

›Beta blockers or non-dihydropyridine calcium channel blockers Class I recommendation

09Special Populations/sp31

Pregnancy

›Pregnancy considerations

›Maternal stabilization priority

›Synchronized cardioversion safe when unstable

›Left lateral tilt for late pregnancy hypotension risk

›Rate control medication selection

›Beta blockers preferred for acute control with fetal monitoring as indicated

›Avoid atenolol for chronic use due to fetal growth restriction association

›Anticoagulation selection

›LMWH preferred for therapeutic anticoagulation in pregnancy

›Warfarin teratogenicity risk in first trimester

›DOACs generally avoided due to limited safety data

Geriatric

›Geriatric considerations

›Presentation patterns

›Fatigue and dyspnea more common than palpitations

›Delirium as primary manifestation

›Medication risks

›Hypotension sensitivity with diltiazem and beta blockers

›Bradycardia risk with combination therapy

›Anticoagulation emphasis

›Higher baseline stroke risk

›Fall risk alone not a contraindication to anticoagulation

Pediatrics

›Pediatric considerations

›Epidemiology

›Atrial fibrillation rare in structurally normal hearts

›Congenital heart disease and postoperative states as common contexts

›Workup focus

›Structural heart disease screening

›Toxicology consideration in adolescents

›Management

›Early cardiology involvement

›Weight based dosing for rate control agents per pediatric protocols

10Background/b35

Epidemiology

›Epidemiology basics

›Prevalence

›Most common sustained arrhythmia in adults

›Prevalence increases markedly with age

›Atrial flutter context

›Often coexists with atrial fibrillation

›Typical flutter is cavotricuspid isthmus dependent

›Outcomes

›Increased stroke risk without anticoagulation

›Increased heart failure risk with uncontrolled rates

Pathophysiology

›Mechanisms

›Atrial fibrillation mechanism

›Multiple wavelet reentry and triggers

›Pulmonary vein ectopy contribution

›Atrial flutter mechanism

›Macroreentrant circuit in right atrium for typical flutter

›Fixed atrial rate leading to predictable ventricular conduction ratios

›Complications

›Left atrial appendage thrombus formation

›Tachycardia induced cardiomyopathy

Therapeutic Considerations

›Rate versus rhythm strategy

›Rate control advantages

›Rapid symptom improvement for many patients

›Lower procedural risk than cardioversion

›Rhythm control advantages

›Symptom relief when rate control inadequate

›Potential reduction in tachycardia induced cardiomyopathy

›Early rhythm control concept

›Potential long term benefit in selected patients with recent onset atrial fibrillation

›Anticoagulation rationale

›Stroke risk driven by comorbidity more than rhythm pattern

›Typical flutter carries thromboembolic risk similar to atrial fibrillation in many patients

›Ablation considerations

›Typical flutter ablation high success with low recurrence

›Atrial fibrillation ablation considered for symptomatic recurrent atrial fibrillation despite medical therapy

11Patient Discharge Instructions/pdi23

copy discharge instructions

›Discharge education

›Diagnosis and expectations

›Atrial fibrillation or atrial flutter explanation in simple language

›Heart rate control goal

›Medication instructions

›Exact dose and schedule

›Missed dose instructions per medication type

›Anticoagulation safety

›Bleeding precautions

›Avoid NSAIDs unless clinician approved

›Inform dentist and clinicians about anticoagulant use

›Return to ED now triggers

›Chest pain

›Shortness of breath at rest

›Fainting

›New weakness or speech trouble

›Uncontrolled bleeding

›Black stools or vomiting blood

›Severe headache or head injury while on anticoagulant

›Follow-up plan

›Appointment date or timeframe

›ECG reassessment plan

›Anticoagulation monitoring plan if warfarin

12References/r17

Clinical guidelines and key sources

›Guideline sources

›AHA ACC HRS guideline for atrial fibrillation management

›Class I recommendations for urgent cardioversion in instability

›Class I recommendations for anticoagulation by CHA2DS2-VASc

›ESC guideline for atrial fibrillation management

›Integrated care approach and anticoagulation guidance

›Cardioversion anticoagulation duration guidance

›Evidence and tools

›CHA2DS2-VASc validation studies

›Stroke risk stratification support

›Broad external validation

›HAS-BLED development and validation studies

›Bleeding risk identification for modifiable factors

›Not a reason alone to withhold anticoagulation

›Trials comparing rate versus rhythm control strategies

›Symptom driven selection support

›Early rhythm control evidence in selected populations

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed June 16, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.